Combination studies with gemcitabine in the treatment of non-small-cell lung cancer.
Phase II studies have confirmed gemcitabine (GEMZAR) to be an active single agent in treating non-small-cell lung cancer (NSCLC), with response rates averaging 21%. Toxicity, including myelosuppression, is mild, making gemcitabine an attractive agent to consider in combination regimens. Most experie...
| Main Author: | |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Nature Publishing Group|1
1998
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2062800/ |